University of Texas's MD Anderson Cancer Center: Targeting Interleukin-6 Could Help Relieve Immunotherapy Side Effects
May 10, 2022
May 10, 2022
HOUSTON, Texas, May 10 (TNSJou) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
- Study shows combined IL-6 and immune checkpoint blockade reduces toxicity while preserving anti-tumor immune response
* * *
Researchers at The University of Texas MD Anderson Cancer Center have identified a novel strategy to reduce immune-related adverse events from immunotherapy treatment by targeting the cytok . . .
* * *
- Study shows combined IL-6 and immune checkpoint blockade reduces toxicity while preserving anti-tumor immune response
* * *
Researchers at The University of Texas MD Anderson Cancer Center have identified a novel strategy to reduce immune-related adverse events from immunotherapy treatment by targeting the cytok . . .